Stockscreener 앱 받기
17.37
0.00%
0.00
시간 외 거래:
17.37
전일 마감가:
$17.37
열려 있는:
$17.21
하루 거래량:
1.45M
Relative Volume:
0.73
시가총액:
$2.87B
수익:
-
순이익/손실:
$-446.21M
주가수익비율:
-4.9021
EPS:
-3.5434
순현금흐름:
$-423.92M
1주 성능:
+0.46%
1개월 성능:
-11.69%
6개월 성능:
-17.99%
1년 성능:
+45.97%
1일 변동 폭
$17.15
$17.96
1주일 범위
$15.87
$17.96
52주 변동 폭
$8.06
$25.00
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.37 | 2.87B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - AOL.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Dyne Therapeutics (DYN) director buys 2,500 Common Stock shares - Stock Titan
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission (DYN) - Seeking Alpha
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - Yahoo Finance
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics, Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Dyne Therapeutics (DYN) Launches Phase 3 FORZETTO Trial for Duch - GuruFocus
Dyne Therapeutics Launches Late-Stage Trial for DMD Therapy - Intellectia AI
Dyne stock spikes as Duchenne trial launches (DYN:NASDAQ) - Seeking Alpha
DYN: 2026 will focus on DMD and DM1 launches, confirmatory trials, and pipeline expansion - TradingView
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data - TradingView
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval - Investing News Network
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - Moomoo
Duchenne trial of z-rostudirsen tied to U.S. accelerated approval bid - Stock Titan
Dyne Therapeutics launches phase 3 trial for DMD treatment - Investing.com
Dyne Therapeutics launches phase 3 trial for DMD treatment By Investing.com - Investing.com Australia
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - The Manila Times
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - The Motley Fool
MSN Money - MSN
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - Moomoo
DYN Maintained by Evercore ISI Group -- Price Target Lowered to $33 - GuruFocus
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN) - Stock Titan
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake - Stock Titan
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CFO Sells 1,448 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares - MarketBeat
Dyne therapeutics CFO Lucera sells $26,585 in company stock By Investing.com - Investing.com Canada
Breakthrough Findings from Dyne Therapeutics (DYN) Enhance Marke - GuruFocus
Dyne therapeutics CFO Lucera sells $26,585 in company stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU taxes - Stock Titan
Dyne Therapeutics (DYN) CFO logs automatic 1,448-share tax-related sale - Stock Titan
Dyne Therapeutics (DYN) CEO’s 3,311-share sale is automatic tax withholding - Stock Titan
Lifesci Capital Issues Optimistic Outlook for DYN Earnings - MarketBeat
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):